VANCOUVER, British Columbia and BOSTON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, ...
VANCOUVER, British Columbia, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today outlined progress within its pipeline ...
Xenon Pharmaceuticals has a strong cash position of $652.2M and an estimated cash runway of approximately 3.11 years. The company's financial health is commendable, but widening net losses and ...
Xenon (NASDAQ:XENE) Pharmaceuticals Inc (NASDAQ:XENE), a biopharmaceutical company focused on developing innovative therapeutics for neurological disorders, is making significant strides in its ...
FDA Grants Rare Pediatric Disease Designation to XEN007 for Alternating Hemiplegia of Childhood (AHC); Xenon Eligible to Apply for Priority Review Voucher IND for XEN1101 Accepted; Site Selection and ...
A live webcast of the company presentation will be available on the “Investors” section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback